HS 20089
Alternative Names: HS-20089Latest Information Update: 21 Mar 2025
At a glance
- Originator Shanghai Hansoh Biomedical
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase I Solid tumours
Most Recent Events
- 07 Mar 2025 Hansoh BioMedical R&D Company plans a phase III trial for Ovarian cancer (Recurrent, Second-line therapy or greater) in China (IV) in March 2025 (NCT06855069)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (IV, Infusion)
- 11 Apr 2024 Phase-I clinical trials in Solid tumours in China (IV) (NCT06336707)